Importing lower drug prices from abroad may seem like fair play. But it would be a dangerous bargain for Americans.
President Trump’s State of the Union address featured several promising healthcare ideas.
Expanding access to patient-owned health savings accounts and routing federal subsidies through them, rather than through insurance companies, would unleash competition by empowering consumers to spend their healthcare dollars as they see fit. So would stronger price transparency requirements.
But one proposal the president continues to champion would move American healthcare in the opposite direction. And that’s his push for “most-favored-nation” drug pricing.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
Most-Favored-Nation Pricing Would Import Europe’s Drug Rationing
Sally C. Pipes
Importing lower drug prices from abroad may seem like fair play. But it would be a dangerous bargain for Americans.
President Trump’s State of the Union address featured several promising healthcare ideas.
Expanding access to patient-owned health savings accounts and routing federal subsidies through them, rather than through insurance companies, would unleash competition by empowering consumers to spend their healthcare dollars as they see fit. So would stronger price transparency requirements.
But one proposal the president continues to champion would move American healthcare in the opposite direction. And that’s his push for “most-favored-nation” drug pricing.
Read the entire op-ed here.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.